Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03291782 · ClinicalTrials.gov registry record · Phase 1
D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers
A Phase 1 study, sponsored by InventisBio Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT03291782: Completed Phase 1 study, sponsored by InventisBio Co..
NCT03291782 is a Phase 1 study that has completed, run by InventisBio Co.. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03291782, a Phase 1 study, has completed, sponsored by InventisBio Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This initial clinical study in the US will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, and sequential cohort study to evaluate the safety, tolerability, PK and PD of D-0120-NA in fasting, healthy volunteers (HVs). In food effect cohort, subjects will each receive 2 doses of D-0120-NA in an open-label manner; once in the fasted state and once in the fed state.
Primary Outcome
Adverse Events and changes of Laboratory, Electrocardiogram, and Vital Signs
Interventions
- DRUG D-0120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2018-08-06 |
| Phase | Phase 1 |
What the finished NCT03291782 record still lists
NCT03291782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 1 intervention - of which D-0120 is the first listed.
NCT03291782 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03291782 about?
NCT03291782 is a clinical study titled "D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers". This initial clinical study in the US will be a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, and sequential cohort study to evaluate the safety, tolerability, PK and PD of D-0120-NA in fasting, healthy volunteers (HVs). In food effect cohort, subjects will each receiv...
What is the current status of trial NCT03291782?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2017-09-13. Estimated completion is 2018-08-06.
What interventions are being tested in trial NCT03291782?
The interventions under investigation include: D-0120 (DRUG).
Who is sponsoring clinical trial NCT03291782?
This trial is sponsored by InventisBio Co., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03291782's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI